Heart failure breakthrough? trial tests stopping Beta-Blockers in recovered patients

NCT ID NCT06518694

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether people with heart failure whose heart function has returned to normal can safely stop taking beta-blockers. About 1,300 participants will either gradually stop their beta-blockers or continue them as usual. The goal is to see if stopping the drug leads to a relapse of heart failure or other heart problems, while potentially reducing side effects and medication burden.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: beta-blockers (discontinued with tapering)
What this could lead to: If successful, this could show that some heart failure patients with normalized heart function no longer need beta-blockers, simplifying their treatment and improving quality of life.
What could go wrong: This is a Phase 3 trial, but it's still uncertain whether stopping beta-blockers is safe. There is a risk of heart failure relapse, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Death heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Hôpital Européen Georges Pompidou
RECRUITING

Paris, IDF, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.